Leerink Partnrs Issues Optimistic Forecast for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.65 EPS and FY2029 earnings at $2.10 EPS.

A number of other analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.93.

ACADIA Pharmaceuticals Stock Down 2.8 %

ACAD stock opened at $14.57 on Wednesday. The stock’s 50 day moving average is $17.32 and its two-hundred day moving average is $16.93. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $20.68. The company has a market capitalization of $2.43 billion, a PE ratio of 18.68 and a beta of 0.54.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total value of $40,132.56. Following the sale, the executive vice president now directly owns 59,456 shares in the company, valued at $881,137.92. The trade was a 4.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,169 shares of company stock valued at $242,686 over the last three months. Company insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the last quarter. Barclays PLC grew its position in ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after purchasing an additional 154,854 shares in the last quarter. Burney Co. purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $6,953,000. Proficio Capital Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $272,000. Finally, State Street Corp grew its position in ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock worth $91,878,000 after acquiring an additional 173,084 shares in the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.